Alnylam为5.75亿美元的可转换优先票据定价

• Alnylam Pharmaceuticals (NASDAQ:ALNY) priced its previously announced private offering of $575M aggregate principal amount of 0.00% convertible senior notes due 2028.
• The size of the offering was increased from the previously announced offering of $500M aggregate principal amount of notes.
• Initial purchasers have an option to purchase up to an additional $86.25M aggregate principal amount of the notes.
• The offering is expected to close on September 12, 2025.
• Net proceeds will be approximately $561.6M (or ~$645.9M if the initial purchasers exercise their option to purchase additional notes).
• The company intends to use ~$30.7M to pay the cost of the capped call transactions; the remainder to repurchase for cash ~$637.8M convertible senior notes due 2027.

More on Alnylam Pharmaceuticals

• Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
• Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
• Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
• Alnylam announces proposed offering of $500M convertible senior notes
• Alnylam to advance Roche-partnered heart drug to late-stage trial despite mid-stage setback